March 25 (Reuters) - Axsome Therapeutics' (AXSM.O), opens new tab experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder in ...

Needham estimates 2028 US sales of ~$550 million (+11% vs. cons), growing to ~$1 billion in 2030 Axsome receives no value for its remaining pipeline, but several of these products are in the late ...

RBC Capital initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), citing that its near-term revenue growth and pipeline optionality are underappreciated. RBC Capital says Auvelity, a key value ...

The U.S. Food ​and Drug Administration has approved Axsome Therapeutics' drug to treat agitation ‌in patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

One of the few popular drug stocks not tied to weight loss, Axsome Therapeutics sank 13% when the company reported mixed outcomes in two Alzheimer’s studies on Monday. In one study, the company’s drug ...

The old healthcare model is breaking down.

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to ...

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a decade. Axsome, maker of the ...